News
Novartis nabs first CAR T approval in Canada
Health Canada has approved its first chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel (Kymriah).
News
England green-lights coverage of one CAR T-cell therapy
Tisagenlecleucel (Kymriah) will be available for certain leukemia patients through the Cancer Drugs Fund.
News
Researchers find drug target in anaplastic large-cell lymphoma
A new study suggests TYK2 is expressed in all cases of ALCL.
News
Cancer researchers fall short on financial disclosures
The study found that undisclosed speaking fees, grants, and research payments were common.
News
Caplacizumab approved in Europe to treat aTTP
The drug is under priority review by the U.S. Food and Drug Administration.
News
How to bridge the gap for rural cancer patients
A new study finds outcomes are similar for rural and urban cancer patients when enrolled in clinical trials.
News
Blinatumomab gains European approval in children
The drug was approved in Europe for adults in 2015.
News
Daratumumab approved in Europe for new myeloma indication
The drug is now authorized for use in combination with bortezomib, melphalan, and prednisone to treat adults with newly diagnosed multiple myeloma...
News
FDA approves new factor VIII product for hemophilia A
Jivi is approved for on-demand treatment and as routine prophylaxis.
News
European Commission approves first CAR T-cell therapies
Tisagenlecleucel and axicabtagene ciloleucel can now be marketed throughout Europe.
News
FDA approves ibrutinib with rituximab in Waldenström’s macroglobulinemia
Ibrutinib is already approved as a single agent in Waldenstrom’s macroglobulinemia.
News
Elotuzumab under review for relapsed/refractory myeloma
The Food and Drug Administration is expected to make an approval decision by the end of 2018.
News
Marzeptacog alfa reduces bleeding episodes in hemophilia with inhibitors
Early results were presented at the Hemophilia Drug Development Summit in Boston.
News
FDA grants orphan designation to DHODH inhibitor for AML
ASLAN003 is a second-generation DHODH inhibitor in phase 2 trials.